Nuvectis Pharma Inc NVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $18.60
- Day Range
- $18.04–19.21
- 52-Week Range
- $5.55–29.28
- Bid/Ask
- $19.14 / $19.22
- Shares Outstanding
- 31.53M
- Market Cap
- $603.40M
- Volume/Avg
- 331,000 / 264,449
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.nuvectis.com
Valuation
|
Metric
|
NVCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 35.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NVCT
|
|---|---|
Quick Ratio | 2.25 |
Current Ratio | 2.27 |
Interest Coverage | — |
Quick Ratio
NVCT
Profitability
|
Metric
|
NVCT
|
|---|---|
Return on Assets (Normalized) | −68.89% |
Return on Equity (Normalized) | −109.27% |
Return on Invested Capital (Normalized) | −115.13% |
Return on Assets
NVCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%Wwk!w | LOCK|n%<fz | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$&<J@> | LOCK|ftVy | $71B | |||
| argenx SE ADR
ARGX
| LOCK|z!s#@! | LOCK|HzY | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bKf?#G | LOCK|nZ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@PQjb<C | LOCK|z&R> | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GRdH#Mh | LOCK|$GC@ | $26B | |||
| Moderna Inc
MRNA
| LOCK|%VLH@T! | LOCK|wB | $25B | |||
| Incyte Corp
INCY
| LOCK|tZdsSv | LOCK|w<> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!jfbR#b | LOCK|&# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|RZ!Jy? | LOCK|q>X | $16B |
United States